Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. - Wikidata - wikimedia - TriplyDB

Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda.

Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda.

http://www.wikidata.org/entity/Q35891202

about

Adjunctive steroid therapy for managing pulmonary tuberculosis Corticosteroids for tuberculous pleurisy Changes in CD4+ T-cells and HIV RNA resulting from combination of anti-TB therapy with Dzherelo in TB/HIV dually infected patients Immunotherapy for tuberculosis: future prospects Tuberculosis vaccines and prevention of infection Novel adjunctive therapies for the treatment of tuberculosis Diagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor Therapy Persistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challenge Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model Corticosteroids for tuberculous pleurisy.The immunology of tuberculosis: from bench to bedside.Treatment Options for HIV-Associated Tuberculosis.Diagnosis and Treatment of Latent Tuberculosis Infection due to Initiation of Anti-TNF Therapy.HIV: treating tuberculosis.Lactoferrin modulation of mycobacterial cord factor trehalose 6-6'-dimycolate induced granulomatous response.Advancing host-directed therapy for tuberculosis.A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL.Influence of oral lactoferrin on Mycobacterium tuberculosis induced immunopathology.Lean tissue mass wasting is associated with increased risk of mortality among women with pulmonary tuberculosis in urban Uganda Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome Clinical review: a systematic review of corticosteroid use in infections.Targeting Batf2 for infectious diseases and cancer.Evidence base for using corticosteroids to treat HIV-associated immune reconstitution syndrome.Unexpected low-level viremia among HIV-infected Ugandan adults with untreated active tuberculosis.Immunological options for the treatment of tuberculosis: evaluation of novel therapeutic approaches.Preventing Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in High-Risk Patients: Protocol of a Randomized Placebo-Controlled Trial of Prednisone (PredART Trial).Treatment of tuberculosis in children.Wasting among Uganda men with pulmonary tuberculosis is associated with linear regain in lean tissue mass during and after treatment in contrast to women with wasting who regain fat tissue mass: prospective cohort study.Immunoregulation in TB: observations and implications Cytokine therapy of tuberculosis at the crossroads.Atherosclerosis: pathogenesis and increased occurrence in individuals with HIV and Mycobacterium tuberculosis infection Immunity to TB and targets for immunotherapy.Immunotherapy for TB.Shortening the 'short-course' therapy- insights into host immunity may contribute to new treatment strategies for tuberculosis.Inflammation and tuberculosis: host-directed therapies.Corticosteroid effects on sputum culture in pulmonary tuberculosis: a meta-regression analysis.Extremely high HIV-1 viral load in a patient with undiagnosed clinical indicator disease for HIV infection.Immunoadjuvant Therapy and Noninvasive Ventilation for Acute Respiratory Failure in Lung Tuberculosis: A Case Study Paradoxical response with increased tumor necrosis factor-α levels to anti-tuberculosis treatment in a patient with disseminated tuberculosis.

P2860

Q24188019-49880F3A-DDAE-4CD1-B2AA-56AB666909F3 Q24242917-A5A11150-DE19-4C23-A46C-14986F4AF73C Q24653869-D88443E7-59B1-4A30-9B60-A34A693587D5 Q26741261-B4DB4655-8F4C-4AAC-A96B-449468FEAB67 Q26782022-7F3B5017-7D7A-4C97-A223-9A8387A00602 Q26829957-52E41D26-764E-4FFB-90F4-A0289D45F248 Q27005716-C145745A-8BA0-4D3D-B0CB-8E70164CE482 Q28088557-58D6B3E7-A844-4DD3-9B2D-313766F66D82 Q28477281-220DA3AF-3A4A-4631-8339-77A428031F70 Q28480511-C9200303-A4FE-46A2-AE7F-A289AD2CE836 Q33772120-25411931-8272-49E6-B867-9B52EAB020A4 Q33777367-27CD8812-C621-4B69-9137-42C5C4DCE4D6 Q33813097-C668DA9E-7D76-429E-93A3-F2851F833504 Q33882852-53ED6841-1AED-47B1-8F4B-A079688D5958 Q33950001-E4AD60AE-C0C3-4AB9-ADB1-3210204F5819 Q34166235-CF48192B-C539-48EC-A5C9-3A68CDEE519D Q34466861-EEFE1002-E984-49B8-B953-200D98EF541C Q35167145-22AC11EB-8D8B-47F2-890A-23077F29E4A9 Q35643199-7FE09FB8-BF5F-4040-B000-A5D0A55A16C4 Q36040147-A1140F6F-A518-46EE-BC5B-C4142EAC1F72 Q36238260-14DF0B14-A60C-4E81-8D52-48C9DDA8763D Q36342706-425E079A-E26B-48A8-A560-C7592DAE852F Q36413539-D3D6D03A-847A-4B7C-89DF-32315125DBC1 Q36505513-7264FBE8-4A78-4838-A271-F8FD42A27BF7 Q36576084-F908CF29-BC71-465C-9321-26B598C5E7FA Q36839739-1816B89C-DF65-4C75-B714-4927DD05F8F0 Q37250893-A068B4C3-338E-47AA-B12F-8EEC65A44754 Q37340569-0BBDF034-C183-488A-A8B4-C8E2CB1F86F2 Q37580878-34AF886A-1742-4F71-8F99-965E1D13889C Q37742701-6F87CFEB-80D3-4D22-9495-BD7E260A87B0 Q37754962-4CFEF293-5F00-43ED-9233-D058F795608B Q37957875-92F26D4E-5EA0-49BD-AA83-ADA46AA1D310 Q37984571-79DBF7ED-9AAF-4E62-AEA3-023E1CA8B92D Q38025666-4CEC5604-C881-4295-841D-A11296EE6789 Q38075095-CF6FB1A0-4F4D-494B-B63D-2903496F2A3C Q38203352-5F49FD2D-40A3-47AA-9B3D-DE71DFD08F1F Q39033554-53F15F70-FB3A-4097-8A3F-8E293433F240 Q40896265-331F486E-00C4-4BA1-B181-163527267E6E Q42108310-71A907AB-0F51-4BAB-8E29-BCEA628D1144 Q42317119-363653B5-1448-4D59-88B3-D1077222E696

P2860

Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda.

http://www.wikidata.org/entity/Q35891202

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Immunoadjuvant prednisolone th ...... se 2 clinical trial in Uganda.

@ast

Immunoadjuvant prednisolone th ...... se 2 clinical trial in Uganda.

@en

type

label

Immunoadjuvant prednisolone th ...... se 2 clinical trial in Uganda.

@ast

Immunoadjuvant prednisolone th ...... se 2 clinical trial in Uganda.

@en

prefLabel

Immunoadjuvant prednisolone th ...... se 2 clinical trial in Uganda.

@ast

Immunoadjuvant prednisolone th ...... se 2 clinical trial in Uganda.

@en

P1433

Q35891202-4CFCF80D-F41B-44F9-85FB-AE2FA40933B7

P1476

Q35891202-55BF9CD7-6B7E-4CC8-87E1-58D3080E1F0C

P2093

Q35891202-2E519422-E61F-4119-9A5C-7E4BA89BBFD7

Q35891202-42A9463E-C21E-49D6-991D-C75984928C94

Q35891202-60916475-D8B6-467D-BD94-01BA7149554B

Q35891202-BF00A9E5-B98F-471C-BEB7-20F2986F3793

Q35891202-EF98FE78-2234-489D-B9DA-C4DA9ECD91BD

P2860

Q35891202-03B6C131-8CFD-4F62-B544-D4E662B155D7

Q35891202-08A0A54A-E8B1-4846-9E89-05CCB7392C6E

Q35891202-0A41C86D-CC25-4EAF-A2D5-13A4C80DE26E

Q35891202-0CED39A8-E354-4C56-8653-8D4D3204A59B

Q35891202-1E06CD6D-29E0-4E49-B850-CB37E281229D

Q35891202-24272401-3582-4B9A-9B4B-128BEDE6E688

Q35891202-24F29182-DB69-4E07-ADDF-1B7458E60ECB

Q35891202-2D94F306-4A43-4676-9E69-B56F9CBAB65B

Q35891202-2E68E762-793D-4D18-BF38-F9F4FA5D9162

Q35891202-370E0D04-54C6-4F00-B8BA-6D50E657D408

P304

Q35891202-CBD8F30F-9718-417D-8D43-9C79FB0A7AD9

P31

Q35891202-C6686DBD-C17C-4657-8AE5-A5CDB290D2D2

P356

Q35891202-6EE54081-8952-4CE7-9F6F-5CB244D320ED

P407

Q35891202-95F6209B-B750-453D-B6AB-D08DC22DB8A4

P433

Q35891202-CD50DE36-F86B-4FB3-A426-38ADBA5E00DC

P478

Q35891202-06EC0430-71DB-4AFA-8FE7-21E09E820918

P50

Q35891202-36426181-6A8C-4E84-A8FE-247E4E934E98

Q35891202-8C18B12A-0E18-40BA-BDAD-BFB60B0AB3EA

Q35891202-DF4B1061-4D0D-414B-A059-4357634817FA

P577

Q35891202-8086020B-CD7D-4C61-AAAC-30350C1F3272

P5875

Q35891202-D1805697-E8D9-4EF6-9C22-BF685EF6513D

P698

Q35891202-A120F92F-FFFA-4EB6-BD1A-131E7DA72FF8

P921

Q35891202-1E24EB3B-38C2-4A43-BC3F-F4558799EDBF

Q35891202-268904B5-0042-4290-9DE6-6E755DECB645

Q35891202-61059A79-7EF1-431E-BA23-CA94840D7BE7

P932

Q35891202-2C9F426C-720B-40D2-9F7D-A6F3CD0A11FD

P356

P1433

The Journal of Infectious Diseases

P1476

Immunoadjuvant prednisolone th ...... ase 2 clinical trial in Uganda

@en

P2093

Alphonse Okwera

http://www.w3.org/2001/XMLSchema#string

Christopher C Whalen

http://www.w3.org/2001/XMLSchema#string

Robert S Wallis

http://www.w3.org/2001/XMLSchema#string

Roy D Mugerwa

http://www.w3.org/2001/XMLSchema#string

Uganda-Case Western Research Collaboration

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

Long-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infection

Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Random-effects models for longitudinal data

Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B

Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice

Does tuberculosis accelerate the progression of HIV disease? Evidence from basic science and epidemiology.

Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda.

Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease.

P304

856-865

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/427995

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

191

http://www.w3.org/2001/XMLSchema#string

P50

Harriet Mayanja-Kizza

Edward Jones Lopez

P577

2005-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8016463

http://www.w3.org/2001/XMLSchema#string

P698

15717259

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

phase II clinical trial

P932

4515766

http://www.w3.org/2001/XMLSchema#string